MT-601 demonstrates favorable safety and durable responses in relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL)
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Geoffrey Shouse, Samuel Yamshon, Manali Kamdar, Haitham Abdelhakim, Priyanka Pophali, Luke Mountjoy, Aravind Ramakrishnan, Ian Flinn, Akiva Diamond, Margaret Gilbert, Maria-Bernadette Madel, Laura Angelo, Hettie Stein, Deb Chapman, Patricia Allison, John Gutheil, Teresa Melink, Susie Bergman, Mary Newman, Helen Heslop, Malcolm Brenner, Premal Lulla, Monic Stuart, Juan Vera
Institutions: City Of Hope National Medical Center, Weill Cornell Medicine, University of Colorado Cancer Center, University of Kansas Medical Center, University of Wisconsin Carbone Cancer Center, Colorado Blood Cancer Institute, St David's Medical Center, Tennessee Oncology, Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, Houston Methodist, Texas Children's Hospital
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417009710